X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through agreement, Vaccinex allows companies to access the ActivMAb platform, which enables the discovery and development of antibodies with high selectivity and novel mechanisms of action against complex membrane proteins.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 21, 2024
Details:
The net proceeds will be used for the development of VX15/2503 (pepinemab), which is a monoclonal antibody that focuses on the inhibition of semaphorin 4D for the treatment of head and neck cancer, Huntington’s Disease and Alzheimer’s Disease.
Lead Product(s): Pepinemab
Therapeutic Area: Neurology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 07, 2024
Details:
The Company intends to use the net proceeds to fund the ongoing development and clinical trials of its lead drug candidate, VX15/2503 (pepinemab), blocks SEMA4D, a potent biological effector that it believes triggers inflammation, in Alzheimer’s disease and cancer.
Lead Product(s): Pepinemab
Therapeutic Area: Neurology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 28, 2023
Details:
VX15/2503 (pepinemab) is a humanized IgG4 mAb that inhibits SEMA4D, which regulates the actin cytoskeleton of cells that plays an important role in inflammatory reactions in the brain as well as in tumor immune evasion. It is being developed in combination for alzheimer's.
Lead Product(s): Pepinemab
Therapeutic Area: Neurology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Vaccinex intends to use the net proceeds from the private placement to fund the ongoing development and clinical trials of its lead drug candidate, VX15/2503 (pepinemab), an IgG4 humanized monoclonal antibody targeting SEMA4D, in Alzheimer’s disease and in cancer.
Lead Product(s): Pepinemab
Therapeutic Area: Neurology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2023
Details:
VX15/2503 (pepinemab) is a human IgG4 mAb that promotes infiltration and activation of dendritic cells and CD8+ T-cells and reverses immunosuppression within the tumor microenvironment. It is being developed in combination with keytruda for R/M HSNCC.
Lead Product(s): Pepinemab,Avelumab
Therapeutic Area: Oncology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
VX15/2503 (pepinemab) is a human IgG4 mAb that promotes infiltration and activation of dendritic cells and CD8+ T-cells and reverses immunosuppression within the tumor microenvironment. It is being developed in combination with keytruda for R/M HSNCC.
Lead Product(s): Pepinemab,Pembrolizumab
Therapeutic Area: Oncology Product Name: VX15/2503
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
SRF114 is a fully human, afucosylated anti-CCR8 antibody designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment.
Lead Product(s): SRF114
Therapeutic Area: Oncology Product Name: SRF114
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Vaccinex intends to use the net proceeds from the private placement to fund the ongoing development and clinical trials of its lead drug candidate, pepinemab, in cancer and neurodegenerative disease and for working capital and general corporate purposes.
Lead Product(s): Pepinemab
Therapeutic Area: Genetic Disease Product Name: VX15/2503
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator:
Deal Size: $3.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 28, 2022
Details:
VX15/2503 (pepinemab) antibody blockade SEMA4D in early Huntington’s Disease analysis showed trial did not meet primary endpoints, brain imaging measures showed significant reduction in atrophy of caudate nucleus and prevented loss of metabolic activity in most brain regions.
Lead Product(s): Pepinemab
Therapeutic Area: Genetic Disease Product Name: VX15/2503
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
